Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209–249

Article  PubMed  Google Scholar 

Halperin DM, Varadhachary GR (2014) Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter? Curr Oncol Rep 16:366

Article  PubMed  Google Scholar 

Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049–1057

Article  PubMed  Google Scholar 

Faris JE, Wo JY (2013) The controversial role of chemoradiation for patients with locally advanced pancreatic cancer. Oncologist 18:981–985

Article  PubMed  PubMed Central  Google Scholar 

Casadei R, Ricci C, Pezzilli R et al (2010) A prospective study on radiofrequency ablation locally advanced pancreatic cancer. Hepatobiliary Pancreat Dis Int 9:306–311

PubMed  Google Scholar 

D’Onofrio M, Barbi E, Girelli R et al (2010) Radiofrequency ablation of locally advanced pancreatic adenocarcinoma: an overview. World J Gastroenterol 16:3478–3483

Article  PubMed  PubMed Central  Google Scholar 

Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C (2010) Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 97:220–225

Article  PubMed  Google Scholar 

Vogel JA, van Veldhuisen E, Agnass P et al (2016) Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: a systematic review of experimental studies. PLoS One 11:e0166987

Article  PubMed  PubMed Central  Google Scholar 

Vroomen L, Petre EN, Cornelis FH, Solomon SB, Srimathveeravalli G (2017) Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: what are the differences? Diagn Interv Imaging 98:609–617

Article  PubMed  Google Scholar 

Yarmush ML, Golberg A, Sersa G, Kotnik T, Miklavcic D (2014) Electroporation-based technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 16:295–320

Article  PubMed  Google Scholar 

Tasu JP, Tougeron D, Rols MP (2022) Irreversible electroporation and electrochemotherapy in oncology: state of the art. Diagn Interv Imaging 103:499–509

Article  PubMed  Google Scholar 

Ansari D, Kristoffersson S, Andersson R, Bergenfeldt M (2017) The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy. Scand J Gastroenterol 52:1165–1171

Article  PubMed  Google Scholar 

Casadei R, Ricci C, Ingaldi C et al (2020) Intraoperative electrochemotherapy in locally advanced pancreatic cancer: indications, techniques and results-a single-center experience. Updates Surg 72:1089–1096

Article  PubMed  Google Scholar 

Martin RCG 2nd (2015) Irreversible electroporation of stage 3 locally advanced pancreatic cancer: optimal technique and outcomes. J Vis Surg 1:4

PubMed  PubMed Central  Google Scholar 

Narayanan G, Hosein PJ, Arora G et al (2012) Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol 23:1613–1621

Article  PubMed  Google Scholar 

Paiella S, De Pastena M, D’Onofrio M et al (2018) Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol 3:80

Article  PubMed  PubMed Central  Google Scholar 

Auclin E, Marthey L, Abdallah R et al (2021) Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Br J Cancer 124:1941–1948

Article  PubMed  PubMed Central  Google Scholar 

Varadhachary GR, Tamm EP, Abbruzzese JL et al (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046

Article  PubMed  Google Scholar 

Nielsen K, Scheffer HJ, Vieveen JM et al (2014) Anaesthetic management during open and percutaneous irreversible electroporation. Br J Anaesth 113:985–992

Article  PubMed  Google Scholar 

U.S. Department of Health and Human Services NIoH, National Cancer Institute. (2009) Common Terminology Criteria for Adverse Events version 4.0. US Department of Health and Human Services, Washington, DC

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

Article  PubMed  Google Scholar 

Ducreux MP, Desgrippes R, Rinaldi Y et al (2022) PRODIGE 29 – NEOPAN. A randomized phase III trial comparing folfirinox (FFX) to gemcitabine in locally advanced pancreatic carcinoma (PC)ESMO, Paris

Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406

Article  PubMed  Google Scholar 

Scheffer HJ, Vroomen LG, de Jong MC et al (2017) Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: results of the phase I/II PANFIRE study. Radiology 282:585–597

Article  PubMed  Google Scholar 

Suker M, Beumer BR, Sadot E et al (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801–810

Article  PubMed  PubMed Central  Google Scholar 

Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19:1592–1599

Article  PubMed  Google Scholar 

Petrelli F, Coinu A, Borgonovo K et al (2015) FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas 44:515–521

Article  PubMed  Google Scholar 

Park W, Chawla A, O’Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851–862

Article  PubMed  PubMed Central  Google Scholar 

Ruarus AH, Vroomen L, Geboers B et al (2020) Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology 294:212–220

Article  PubMed  Google Scholar 

Sutter O, Calvo J, N’Kontchou G et al (2017) Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology 284:877–886

Article  PubMed  Google Scholar 

Tasu JP, Vesselle G, Herpe G et al (2016) Irreversible electroporation for locally advanced pancreatic cancer. Diagn Interv Imaging 97:1297–1304

Article  PubMed  Google Scholar 

Lafranceschina S, Brunetti O, Delvecchio A et al (2019) Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. Cancers 11(11):1718. https://doi.org/10.3390/cancers11111718

Article  PubMed  PubMed Central  Google Scholar 

Fritz S, Sommer CM, Vollherbst D et al (2015) Irreversible electroporation of the pancreas is feasible and safe in a porcine survival model. Pancreas 44:791–798

Article  PubMed  Google Scholar 

Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE (2010) Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford) 12:348–351

Article  PubMed  Google Scholar